XML 34 R23.htm IDEA: XBRL DOCUMENT v3.25.3
STOCKHOLDERS' DEFICIT (Tables)
 9 Months Ended
Sep. 30, 2025
Equity [Abstract]  
Schedule of Share-Based Payment Arrangement, Cost by Plan
The following table presents the Company's total share-based compensation expense by award type:

(In thousands)Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
RSUs$4,817 $5,636 $14,162 $15,647 
Performance RSUs6,796 2,150 13,542 6,351 
Options— 477 198 1,965 
Total Share-Based Compensation Expense(1)
$11,613 $8,263 $27,902 $23,963 
(1)Total share-based compensation expense includes $7.6 million and $11.8 million of expense from cash settled awards for the three and nine months ended September 30, 2025, respectively. Total share-based compensation expense includes $1.5 million and $2.0 million of expense from cash settled awards for the three and nine months ended September 30, 2024.
Schedule of Computation of Loss per Share
Computation of Loss per Share
(In thousands, except per share data)Three Months Ended
September 30,		Nine Months Ended
September 30,
 2025202420252024
NUMERATOR:    
Net loss attributable to the Company – common shares$(66,264)$(41,265)$(430,968)$(1,041,431)
DENOMINATOR(1):
   
Weighted average common shares outstanding - basic155,187 151,990 153,991 150,978 
  Stock options and restricted stock(2):
— — — — 
Weighted average common shares outstanding - diluted155,187 151,990 153,991 150,978 
Net loss attributable to the Company per common share:   
Basic$(0.43)$(0.27)$(2.80)$(6.90)
Diluted(0.43)(0.27)(2.80)(6.90)
(1)All of the outstanding Class B common stock and Special Warrants are included in both the basic and diluted weighted average common shares outstanding of the Company for the three and nine months ended September 30, 2025 and 2024.
(2)Outstanding equity service awards representing 10.6 million and 14.8 million shares of Class A common stock of the Company for the three months ended September 30, 2025 and 2024, respectively, and 13.3 million and 15.2 million shares of Class A common stock for the nine months ended September 30, 2025 and 2024, respectively, were not included in the computation of diluted earnings per share because to do so would have been antidilutive.